HS-20094
GIP/GLP-1 · s.c. · Hansoh
Summary
- Also known as
- Hansoh (Regeneron licence ex-China)
- Mechanism
- GIP/GLP-1
- Route
- s.c.
- Company
- Hansoh
- Highest development stage
- filed
- Status (as of data cut)
- Olatorepatide. Phase 3 LIGHTEN positive in China (−18.7 % at 48 weeks, EASD 2026); NDA accepted (June 2026); Regeneron licence ex-China verify
- Next milestone
- China approval; global phase 3 (Regeneron)
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 3 positive phase 3 | Positive phase 3 LIGHTEN (EASD 2026); NDA accepted June 2026 | LIGHTEN (EASD 2026); Hansoh NDA announcement (Jun 2026) |
| T2D | 2 phase 3 ongoing | Phase 3 registered on ClinicalTrials.gov | |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LIGHTEN (HS-20094-301) | 5 mg | obesity china | 48 | 604 | −12.5 % vs −2.7 % Δ −9.8 pp | −11.8 % vs −2.5 % Δ −9.3 pp | — | — | — | — | — | — | — | congress |
| LIGHTEN (HS-20094-301) | 10 mg | obesity china | 48 | 604 | −17.5 % vs −2.7 % Δ −14.8 pp | −17.0 % vs −2.5 % Δ −14.5 pp | — | — | — | — | — | — | — | congress |
| LIGHTEN (HS-20094-301) | 15 mg | obesity china | 48 | 604 | −19.3 % vs −2.7 % Δ −16.6 pp | −18.7 % vs −2.5 % Δ −16.2 pp | — | — | — | — | — | — | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- 5 mg: The release reports no discontinuations for treatment-related adverse events (pooled doses); discontinuation for any adverse event is not reported.
- 10 mg: The release reports no discontinuations for treatment-related adverse events (pooled doses); discontinuation for any adverse event is not reported.
- 15 mg: The release reports no discontinuations for treatment-related adverse events (pooled doses); discontinuation for any adverse event is not reported.
Verbatim quotes from the source (6)
- 5 mg · weight_tp · EQS release
Under the treatment-regimen estimand, mean body weight reductions were
- 5 mg · weight_eff · EQS release
under the efficacy estimand, mean body weight reductions at week 48
- 10 mg · weight_tp · EQS release
Under the treatment-regimen estimand, mean body weight reductions were
- 10 mg · weight_eff · EQS release
under the efficacy estimand, mean body weight reductions at week 48
- 15 mg · weight_tp · EQS release
Under the treatment-regimen estimand, mean body weight reductions were
- 15 mg · weight_eff · EQS release
under the efficacy estimand, mean body weight reductions at week 48
Registered trials (4)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| RISE-1 Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes | Obesity | Phase 3 | not yet recruiting | 2026-11 → 2028-12 | 3000 | not yet recruiting | NCT07896265 |
| NCT07156500 A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone | T2D | Phase 3 | not yet recruiting | 2025-09 → 2027-03 | 204 | not yet recruiting | NCT07156500 |
| NCT07156539 A Phase 3 Study of HS-20094 in Patients With T2DM | T2D | Phase 3 | not yet recruiting | 2025-09 → 2027-03 | 546 | not yet recruiting | NCT07156539 |
| NCT06839664 · China A Study of HS-20094 in Chinese Adults With Overweight or Obesity | Obesity | Phase 3 | completed | 2024-11 → 2026-01 | 604 | Completed; results not in the atlas yet | NCT06839664 |
Primary sources
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd66821.
- Hansoh Pharma. Olatorepatide phase III LIGHTEN data presented at EASD 2026 [EQS-News]. 2026 Oct 2. Available from: https://www.boersennews.de/nachrichten/meldungen/eqs/eqs-news-19-3-weight-loss-at-week-48-phase-data-of-olatorepatide-hansoh-s-dual-biased-glp-1-gip-agonist-presented-at-easd/5297659/
How to cite this page
Cite the primary publication for any single result; every value above links to it.